Lv12
70 积分 2025-06-25 加入
In vivo CAR engineering for immunotherapy
6小时前
待确认
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
6小时前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
1天前
已完结
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
1个月前
已完结
50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow’s Guide in the Clinic
1个月前
已完结
Understanding the impact of psychosocial working conditions on workers’ health: we have come a long way, but are we there yet?
1个月前
已完结
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
3个月前
已完结
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non-Small-Cell Lung Cancer
4个月前
已完结
皖公网安备34019202002308
